Ligand Pharmaceuticals Acquires Ryjunea Royalty Rights for $23M

What Happened
Ligand Pharmaceuticals Incorporated filed a Form 8-K on September 22, 2026, announcing it acquired royalty and milestone payment rights related to Santen Pharmaceutical Co., Ltd.’s Ryjunea from Sydnexis, Inc. The company paid $23 million upfront as part of the transaction. A press release describing the transaction was furnished as Exhibit 99.1 to the 8-K.

Key Details

• Transaction announced on September 22, 2026.
• Upfront cash payment: $23.0 million.
• Asset acquired: royalty and milestone payment rights related to Santen’s Ryjunea.
• Seller: Sydnexis, Inc.; press release included as Exhibit 99.1 to the 8-K.

Why It Matters
This deal gives Ligand the right to receive future royalty and milestone payments tied to Ryjunea sales or development milestones, which could create a new revenue stream without adding operational responsibilities for the product. The $23M upfront payment is a clear, immediate cash deployment; future financial impact depends on Ryjunea’s commercial performance and milestone achievements (amounts and timing of which were not detailed in the 8-K). The filing is a Regulation FD disclosure and provides investors with timely notice of the transaction.